Under the burst of innovation, Chinese pharmaceutical companies began the era of sea 2.0.

"Pharmaceutical Network Industry Dynamics" 10 years ago, China's pharmaceutical exports mainly raw materials, export markets are relatively concentrated in a few key markets, new drug applications are few, low level of research and development, manufacturing research and development outsourcing capacity is weak, so the international competition is mainly reflected in the cost advantage.
According to the data, China's API exports have increased 2.2-fold in the past decade from 4.6036 million tons to 10.1185 million tons, indicating that Chinese API is becoming more popular and more important in the international market.
But after 10 years of development, China's pharmaceutical import structure has begun to change significantly, the proportion of imports of raw materials decreased from 28.79 percent to 14.96 percent, the export structure significantly improved, Western pharmaceutical preparations, medical equipment export capacity increased, increased by 2.6 times, 1.7 times, respectively.
With the improvement of the scale, research and development and innovation of domestic pharmaceutical enterprises, the internationalization of China's pharmaceutical industry has not only been limited to the field of API exports, but also involves preparations, original innovative drugs, capital and other aspects.
, especially in recent years, China's innovative pharmaceutical companies actively participate in the era of navigation, the local new drugs out to sea also began to usher in a new breakthrough.
, as on December 20, 2019, Shi Pharmaceutical Group's innovative drug, Xuanning, was approved by the U.S. Food and Drug Administration (FDA).
, the innovative drug, developed by a local Chinese company, was fully approved by the FDA for listing and received a pass to sell globally.
this breakthrough not only reflects the international recognition of China's new drug research and development level, but also means that Shi medicine will be a new posture on the world stage.
, Ship pharmaceutical group is also through a variety of forms to achieve the sea, including product mergers and acquisitions, technology transfer and so on.
future, Shi pharmaceutical group's internationalization path will gradually transition from product export to capital export, through international expansion of overseas advanced technology and resources to introduce domestic, combined with the application of the local market, and then seek the expansion of overseas markets.
December 26, 2019, Greenlee Pharmaceuticals announced that its self-developed new compound LY03005 has officially filed a new drug listing application (NDA) with the U.S. Food and Drug Administration (FDA).
the drug, which is used to treat depression, is also the second new central nerve drug to be declared NDA in the United States.
, Leaf Pharmaceuticals is stepping up investment to advance the development of new drugs in the field of the disease.
new drugs are already in the NDA or clinical late stage and are expected to be available in major pharmaceutical markets around the world starting in 2020.
In addition, Hengrui Pharmaceuticals, Tianyuan Bio, Taiji Group and other well-known pharmaceutical companies are also through the establishment of overseas business units, product mergers and acquisitions, technology transfer and other ways to accelerate the expansion of overseas markets, the current has achieved remarkable results.
, there is no big pharmaceutical company on the market that is non-international.
the domestic market alone, it is difficult to support the continued growth of a pharmaceutical company after reaching a market capitalization of hundreds of billions.
, expanding overseas markets has become one of the most important development strategies for local pharmaceutical companies.
future, pharmaceutical companies should actively diversify their operations, expand their business sectors vertically and achieve diversified development on the basis of increasing innovation and research and development.
.